4D Molecular (FDMT) Therapeutics announced the appointment of Kristian Humer as CFO. Humer will lead the company’s financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience spanning corporate finance, strategic operations and healthcare investment banking. During his tenure at Citi, he held progressively senior roles, culminating as Managing Director in Citi’s Healthcare Investment Banking Group, where he worked from 2010 to 2021.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
- 4D Molecular price target raised to $32 from $26 at RBC Capital
- 4D Molecular price target lowered to $33 from $38 at Barclays
- 4D Molecular Therapeutics Reports Strategic Gains in Q3 2025
- 4D Molecular sees cash runway into 2H28